Epigenetic transitions: towards therapeutic targets

Bibliography

• MARKS P, RIFKIND RA, RICHON VM, BRESLOW R, MILLER T, KELLY WK: Histone deacetylases and cancer: causes and therapies. Nat. Rev Cancer (2001) 1:194–202.
   PubMed Web of Science ®Google Scholar
• SZYF M: Targeting DNA methylation in cancer. Ageing Res. Rev (2003) 2:299–328.
   PubMed Web of Science ®Google Scholar
• JAENISCH R, BIRD A: Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. (2003) 33:245–254.
   PubMed Web of Science ®Google Scholar
• ••An excellent review discussing a balancebetween active and silent chromatin states and possible consequences on tumour growth.
   Google Scholar
• JOHNSTONE RW: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev Drug Discov (2002) 1:287–299.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of therapeuticapproaches targeting histone deacetylases.
   Google Scholar
• KARPF AR, JONES DA: Reactivating the expression of methylation silenced genes in human cancer. Oncogene (2002) 21:5496–5503.
   PubMed Web of Science ®Google Scholar
• GRUMMT I, PIKAARD CS: Epigenetic silencing of RNA polymerase I transcription. Nat. Rev Ma. Cell Biol (2003) 4:641–649.
   PubMed Web of Science ®Google Scholar
• NAN X, NG HH, JOHNSON CA et al.: Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature (1998) 393:386–389.
   PubMed Web of Science ®Google Scholar
• •Provides evidence that DNA methylation and histone acetylation can be linked by the methyl-CpG-binding protein MeCP2.
   Google Scholar
• FUKS F, BURGERS WA, GODIN N, KASAI M, KOUZARIDES T: Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J. (2001) 20:2536–2544.
   PubMed Web of Science ®Google Scholar
• •Identification of DNMT3a as a corepressor protein associated with DNA-binding transcription factors.
   Google Scholar
• FAHRNER JA, EGUCHI S, HERMAN JG, BAYLIN SB: Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. (2002) 62:7213–7218.
   PubMed Web of Science ®Google Scholar
• DATTA J, GHOSHAL K, SHARMA SM, TAJIMA S, JACOB ST: Biochemical fractionation reveals association of DNA methyltransferase (Dnmt) 3b with Dnmtl and that of Dnmt 3a with a histone H3 methyltransferase and Hdacl. J. Cell. Biochem. (2003) 88:855–864.
   PubMed Web of Science ®Google Scholar
• MACALUSO M, CINTI C, RUSSO G, RUSSO A, GIORDANO A: pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-a in breast cancer. Oncogene (2003) 22:3511–3517.
   PubMed Web of Science ®Google Scholar
• NARLIKAR GJ, FAN HY, KINGSTON RE: Cooperation between complexes that regulate chromatin structure and transcription. Cell (2002) 108:475–487.
   PubMed Web of Science ®Google Scholar
• ROBERT ME MORIN S, BEAULIEU N et al: DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat. Genet. (2003) 33:61–65.
   PubMed Web of Science ®Google Scholar
• OKANO M, BELL DW, HABER DA, LIE: DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell (1999) 99:247–257.
   PubMed Web of Science ®Google Scholar
• •This study shows that DNMT3a and 3b regulate de novo methylation in embryonic stem cells and early embryos.
   Google Scholar
• CHEN T, UEDA Y, DODGE JE, WANG Z, LI E: Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Ma. Cell. Biol. (2003) 23:5594–5605.
   Web of Science ®Google Scholar
• MARGOT JB, EHRENHOFER-MURRAY AE, LEONHARDT H: Interactions within the mammalian DNA methyltransferase family. BMC MoL Biol. (2003) 4:7.
   PubMed Web of Science ®Google Scholar
• RHEE I, BACHMAN KE, PARK BH et al.: DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 416:552–556.
   PubMed Web of Science ®Google Scholar
• ROBERTSON KD, AIT-SI-ALI S, YOKOCHI T, WADE PA, JONES PL, WOLFFE AP: DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat. Genet. (2000) 25:338–342.
   PubMed Web of Science ®Google Scholar
• ROUNTREE MR, BACHMAN KE, BAYLIN SB: DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet. (2000) 25:269–277.
   PubMed Web of Science ®Google Scholar
• NG HH, JEPPESEN P, BIRD A: Active repression of methylated genes by the chromosomal protein MBD1. Ma. Cell. Biol (2000) 20:1394–1406.
   Web of Science ®Google Scholar
• BALLESTAR E, WOLFFE AP: Methyl-CpG-binding proteins. Eur. Biochem. (2001) 268:1–6.
   PubMedGoogle Scholar
• CAI S, HAN HJ, KOHWI-SHIGEMATSU T: Tissue-specific nuclear architecture and gene expression regulated by SATB1. Nat. Genet. (2003) 34:42–51.
   PubMed Web of Science ®Google Scholar
• ROTH SY, DENU JM, ALLIS CD: Histone acetyltransferases. AMU. Rev. Biochem. (2001) 70:81–120.
   PubMed Web of Science ®Google Scholar
• •Review of HAT function and structure.
   Google Scholar
• PELLETIER N, CHAMPAGNE N, LIM H, YANG XJ: Expression, purification, and analysis of MOZ and MORE histone acetyltransferases. Methods (2003) 31:24–32.
   PubMed Web of Science ®Google Scholar
• •This study describes and discusses novel methods for functional characterisation of HATs.
   Google Scholar
• WANG C, FU M, ANGELETTI RH: Direct acetylation of the estrogen receptor a hinge region by p300 regulates transactivation and hormone sensitivity. J. Biol. Chem. (2001) 276:18375–18383.
   PubMed Web of Science ®Google Scholar
• •This study shows that p300 can acetylate non-histone protein, and that acetylation of ER may suppress ligand sensitivity.
   Google Scholar
• DE RUIJTER AJ, VAN GENNIP AH, CARON HN, KEMP S, VAN KUILENBURG AB: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. (2003) 370:737–749.
   PubMed Web of Science ®Google Scholar
• GAO L, CUETO MA, ASSELBERGS F, ATADJA P: Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. Biol. Chem. (2002) 277:25748–25755.
   Web of Science ®Google Scholar
• LAGGER G, O'CARROLL D, REMBOLD M et al: Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. (2002) 21:2672–2681.
   PubMed Web of Science ®Google Scholar
• NORTH BJ, MARSHALL BL, BORRA MT, DENU JM, VERDIN E: The human Sir2 ortholog, SIRT2, is an NAD*-dependent tubulin deacetylase. Ma. Cell (2003) 11:437–444.
   PubMed Web of Science ®Google Scholar
• ONYANGO P, CELIC I, MCCAFFERY JM, BOEKE JD, FEINBERG AP: SIRT3, a human 5IR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc. Natl. Acad. Sci. USA (2002) 99:13653–13658.
   PubMed Web of Science ®Google Scholar
• DAVID G, NEPTUNE MA, DEPINHO RA: SUMO-1 modification of histone deacetylase 1 (HDAC1) modulates its biological activities. .J. Biol. Chem. (2002) 277:23658–23663.
   PubMed Web of Science ®Google Scholar
• •This study shows the effect of post-translational modification on HDAC1 function.
   Google Scholar
• GIRD WOOD D, BUMPASS D, VAUGHAN OA et al: P300 transcriptional repression is mediated by SUMO modification. Mol. Cell (2003)11:1043–1054.
   PubMed Web of Science ®Google Scholar
• JONES PA, BAYLIN SB: The fundamental role of epigenetic events in cancer. Nat. Rev Genet. (2002) 3:415–428.
   PubMed Web of Science ®Google Scholar
• PLASS C: Cancer epigenomics. Hum. Mol. Genet. (2002) 11:2479–2488.
   PubMed Web of Science ®Google Scholar
• COSTELLO JF, FRUHWALD MC, SMIRAGLIA DJ et al.: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. (2000) 24:132–138.
   PubMed Web of Science ®Google Scholar
• ZARDO G, TIIRIKAINEN MI, HONG C et al.: Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors. Nat. Genet. (2002) 32:453–458.
   PubMed Web of Science ®Google Scholar
• HERMAN JG, CIVIN CI, ISSA JP, COLLECTOR MI, SHARKIS SJ, BAYLIN SB: Distinct patterns of inactivation of pl5INK4B and pl6INK4A characterize the major types of hematological malignancies. Cancer Res. (1997) 57:837–841.
   PubMed Web of Science ®Google Scholar
• •This group has developed methylation-specific PCR and demonstrated that inactivation of pl5INK4B and p16INK4A are one of the most common alterations in adult and paediatric leukaemias.
   Google Scholar
• DREXLER HG: Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia (1998) 12:845–859.
   PubMed Web of Science ®Google Scholar
• MALONEY KW, MCGAVRAN L, ODOM LF, HUNGER SP: Acquisition of p16(INK4A) and p15(INK4B) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia. Blood (1999) 93:2380–2385.
   PubMed Web of Science ®Google Scholar
• GUTIERREZ MI, SIRAJ AK, BHARGAVA M et al.: Concurrent methylation of multiple genes in childhood ALL: correlation with phenotype and molecular subgroup. Leukemia (2003) 17:1845–1850.
   PubMed Web of Science ®Google Scholar
• DI CROCE L, RAKER VA, CORSARO M et al: Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science (2002) 295:1079–1082.
   PubMed Web of Science ®Google Scholar
• •Describes the epigenetic role of PML-RAR In differentiation and provides a mechanistic link between genetic and epigenetic changes in carcinogenesis.
   Google Scholar
• PATEL A, GROOPMAN JD, UMAR A: DNA methylation as a cancer-specific biomarker: from molecules to populations. Ann. NY Acad. Sci. (2003) 983:286–297.
   PubMed Web of Science ®Google Scholar
• LEHRMANN H, PRITCHARD LL, HAREL-BELLAN A: Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv. Cancer Res. (2002) 86:41–65.
   PubMed Web of Science ®Google Scholar
• HOWE L, AUSTON D, GRANT P et al: Histone H3 specific acetyltransferases are essential for cell cycle progression. Genes Dev (2001) 15:3144–3154.
   PubMed Web of Science ®Google Scholar
• BORROW J, STANTON VP Jr, ANDRESEN JM et al.: The translocation t(8 ; 16) (p 11 ;p 13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat. Genet. (1996) 14:33–41.
   PubMed Web of Science ®Google Scholar
• DEGUCHI K, AYTON PM, CARAPETI M et al: MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. Cancer Cell (2003) 3:259–271.
   PubMed Web of Science ®Google Scholar
• ROWLEY JD, RESHMI S, SOBULO O et al: All patients with the T(11;16) (q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood (1997) 90:535–541.
   Google Scholar
• IMAMURA T, KAKAZU N, HIBI S et al: Rearrangement of the MOZ gene in pediatric therapy-related myelodysplastic syndrome with a novel chromosomal translocation t(2;8) (p23;p11). Genes Chromosomes Cancer (2003) 36:413–419.
   PubMed Web of Science ®Google Scholar
• GAYTHER SA, BATLEY SJ, LINGER L et al.: Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. (2000) 24:300–303.
   PubMed Web of Science ®Google Scholar
• MURAOKA M, KONISHI M, KIKUCHI-YANOSHITA R: p300 gene alterations in colorectal and gastric carcinomas. Oncogene (1996) 12:1565–1569.
   PubMed Web of Science ®Google Scholar
• CHAMBERS AE, BANERJEE S, CHAPLIN T et al.: Histone acetylation-mediated regulation of genes in leukaemic cells. Eur. J. Cancer (2003) 39:1165–1175.
   PubMed Web of Science ®Google Scholar
• MINUCCI S, MACCARANA M, CIOCE M et al.: Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol. Cell (2000) 5:811–820.
   PubMed Web of Science ®Google Scholar
• WANG J, HOSHINO T, REDNER RL, KAJIGAYA S, LIU JM: ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc. Natl. Acad. Li. USA (1998) 95:10860–10865.
   PubMed Web of Science ®Google Scholar
• BROWN R, STRATHDEE G: Epigenomics and epigenetic therapy of cancer. Trends Mol. Med. (2002) 8:S43–S48.
   PubMed Web of Science ®Google Scholar
• PELICCI PG: A new class of anti-cancer drugs: HDAC-inhibitors. Suppl. Tumori (2002) 1:S66.
   Google Scholar
• ROSATO RR, GRANT S: Histone deacetylase inhibitors in cancer therapy. Cancer Biol. The]: (2003) 2:30–37.
   PubMed Web of Science ®Google Scholar
• KALEBIC T: Epigenetic changes: potential therapeutic targets. Ann. NY Acad. Li. (2003) 983:278–285.
   PubMed Web of Science ®Google Scholar
• SANTINI V, KANTARJIAN HM, ISSA JP: Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann. Intern. Med. (2001) 134:573–586.
   PubMed Web of Science ®Google Scholar
• MARKS PA, MILLER T, RICHON VM:Histone deacetylases. Curc Opin. Pharmacol (2003) 3:344–351.
   PubMed Web of Science ®Google Scholar
• REMISZEWSKI SW: The discovery of NVP-LAQ824: from concept to clinic. Curr. Med. Chem. (2003) 10:2393–2402.
   PubMed Web of Science ®Google Scholar
• KELLY WK, O'CONNOR OA, MARKS PA: Histone deacetylase inhibitors: from target to clinical trials. Expert Opin. Invest. Drugs (2002) 11:1695–1713.
   PubMed Web of Science ®Google Scholar
• TURNER ML, ALTEMUS R, BATES SE: Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood (2001) 98:2865–2868.
   PubMed Web of Science ®Google Scholar
• KELLY WK, RICHON VIVI, O'CONNOR O et al.: Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. (2003) 9:3578–3588.
   Google Scholar
• GOFFIN J, EISENHAUER E: DNA methyltransferase inhibitors - state of the art. Ann. Oncol. (2002) 13:1699–1716.
   PubMed Web of Science ®Google Scholar
• LEONE G, TEOFILI L, VOSO MT, LUBBERT M: DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica (2002) 87:1324–1341.
   PubMed Web of Science ®Google Scholar
• WIJERMANS P, LUBBERT M, VERHOEF G: Low-dose 5-aza-2"-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter Phase II study in elderly patients.' Clin. Oncol. (2000) 18:956–962.
   Web of Science ®Google Scholar
• ESTELLER M: Relevance of DNA methylation in the management of cancer. Lancet Oncol. (2003) 4:351–358.
   PubMed Web of Science ®Google Scholar
• GAUDET F, HOD GSON JG, EDEN A:Induction of tumors in mice by genomic hypomethylation. Science (2003) 300:489–492.
   PubMed Web of Science ®Google Scholar
• EADS CA, NICKEL AE, LAIRD PW: Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Mink) Dnmtl-hypomorphic mice. Cancer Res. (2002) 62:1296–1299.
   PubMed Web of Science ®Google Scholar
• CAMERON EE, BACHMAN KE, MYOHANEN S, HERMAN JG, BAYLIN SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. (1999) 21:103–107.
   PubMed Web of Science ®Google Scholar
• •This study demonstrates the functional synergy between 5-aza-2--deoxycyticline and HDAC inhibitors.
   Google Scholar
• KLISOVIC MI, MAGHRABY EA, PARTHUN MR et al.: Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia (2003) 17:350–358.
   PubMed Web of Science ®Google Scholar
• ZHU WG, OTTERSON GA: The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr. Med. Chem. Anticancer Agents (2003) 3:187–199.
   PubMedGoogle Scholar
• •This review discusses the effects of HDAC inhibitors and demethylating agents used alone and in combination treatment of cancer cells.
   Google Scholar
• ANTOS CL, MCKINSEY TA, DREITZ M et al.: Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J. Biol. Chem. (2003) 278:28930–28937.
   PubMed Web of Science ®Google Scholar
• IGARASHI S, MORITA H, BENNETT KM et al.: Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation. Neuroreport (2003) 14:565–568.
   PubMed Web of Science ®Google Scholar
• HOCKLY E, RICHON VM, WOODMAN B et al.: Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Nati Acad. Sci. USA (2003) 100:2041–2046.
   PubMed Web of Science ®Google Scholar
• DAVIS T, KENNEDY C, CHIEW YE, CLARKE CL, DEFAZIO A: Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Chi'. Cancer Res. (2000) 6:4334–4342.
   PubMed Web of Science ®Google Scholar
• NIMMANAPALLI R, FUINO L, BALI P et al.: Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. (2003) 63:5126–5135.
   PubMed Web of Science ®Google Scholar
• HE LZ, TOLENTINO T, GRAYS ON P et al.: Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. (2001) 108:1321–1330.
   Google Scholar
• AMIR RE, ZOGHBI HY: Rett syndrome: methyl-CpG-binding protein 2 mutations and phenotype-genotype correlations. Am. J. Med. Genet. (2000) 97:147–152.
   PubMed Web of Science ®Google Scholar
• CHEN RZ, AKBARIAN S, TUDOR M, JAENISCH R: Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat. Genet. (2001) 27:327–331.
   PubMed Web of Science ®Google Scholar
• FRANK R, HARGREAVES R: Clinical biomarkers in drug discovery and development. Nat. Rev Drug Discov (2003) 2:566–580.
   PubMed Web of Science ®Google Scholar
• LAIRD PW: The power and the promise ofDNA methylation markers. Nat. Rev Cancer (2003) 3:253–266.
   PubMed Web of Science ®Google Scholar
• ESTELLER M, CORN PG, BAYLIN SB, HERMAN JG: A gene hypermethylation profile of human cancer. Cancer Res. (2001) 61:3225–3229.
   PubMed Web of Science ®Google Scholar
• •This study describes the analysis of promoter hypermethylation changes in 12 genes in more than 600 tumour samples.
   Google Scholar
• KANYAMA Y, HIBI K, NAKAYAMA H et al.: Detection of p16 promoter hypermethylation in serum of gastric cancer patients. Cancer Sci. (2003) 94:418–420.
   PubMed Web of Science ®Google Scholar
• TOYOTA M, AHUJA N, OHE-TOYOTA M, HERMAN JG, BAYLIN SB, ISSA JP: CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Li. USA (1999) 96:8681–8686.
   PubMed Web of Science ®Google Scholar
• SMIRAGLIA DJ, SMITH LT, LANG JC et al.: Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC). J. Med. Genet. (2003) 40:25–33.
   PubMed Web of Science ®Google Scholar
• MARUYAMA R, TOYOOKA S, TOYOOKA K: Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. (2001) 61:8659–8663.
   PubMed Web of Science ®Google Scholar
• RICHON VM, SANDHOFF TW, RIFKIND RA, MARKS PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Li. USA (2000) 97:10014–10019.
   PubMed Web of Science ®Google Scholar
• VRANA JA, DECKER RH, JOHNSON CR et al.: Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bc1-2/13c1-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene (1999) 18:7016–7025.
   PubMed Web of Science ®Google Scholar
• PEART MJ, TAINTON KM, RUEFLI AA et al.: Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. (2003) 63:4460–4471.
   PubMed Web of Science ®Google Scholar
• KIM MS, KWON HJ, LEE YM et al.: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. (2001) 7:437–443.
   PubMed Web of Science ®Google Scholar
• •This paper shows that HDAC inhibitors may suppress tumorigenesis by inhibiting angiogenesis.
   Google Scholar
• CHEN LF, GREENE WC: Regulation of distinct biological activities of the NF-KB transcription factor complex by acetylation."Mol. Med (2003) 81:549–557.
   Web of Science ®Google Scholar
• SHI H, WEI SH, LEU YW et al.: Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res. (2003) 63:2164–2171.
   PubMed Web of Science ®Google Scholar
• ••Novel technology for investigating the functional relationship between DNA methylation and histone acetylation In gene silencing.
   Google Scholar
• GABRIELLI BG, JOHNSTONE RW, SAUNDERS NA: Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: a work in progress. Curr. Cancer Drug Targets (2002) 2:337–353.
   PubMed Web of Science ®Google Scholar
• KANEDA A, TAKAI D, KAMINISHI M, OKOCHI E, USHIJIMA T: Methylation-sensitive representational difference analysis and its application to cancer research. Ann. NY Acad. Sci. (2003) 983:131–141.
   PubMed Web of Science ®Google Scholar